We are live on ! Find out more
INO icon

Inovio Pharmaceuticals
INO

98 hedge funds and large institutions have $49.5M invested in Inovio Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 27 increasing their positions, 20 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

35% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 20

35% more call options, than puts

Call options by funds: $1.71M | Put options by funds: $1.27M

25% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 16

2% more funds holding

Funds holding: 96 → 98 (+2)

1.9% more ownership

Funds ownership: 31.1% → 33% (+1.9%)

24% less capital invested

Capital invested by funds: $65.1M → $49.5M (-$15.6M)

Holders
98
Holders Change
+2
Holders Change %
+2.08%
% of All Funds
1.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
27
Reduced
20
Closed
16
Calls
$1.71M
Puts
$1.27M
Net Calls
+$441K
Net Calls Change
-$506K

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$1.78M
2
BlackRock
BlackRock
New York
+$1.48M
3
Northern Trust
Northern Trust
Illinois
+$1.19M
4
GC
GMT Capital
Georgia
+$1.04M
5
DM
Deerfield Management
New York
+$631K

Top Sellers

1
DTC
Deep Track Capital
Connecticut
-$2.16M
2
Renaissance Technologies
Renaissance Technologies
New York
-$656K
3
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$558K
4
AGM
Alpine Global Management
New York
-$201K
5
CIC
Cornercap Investment Counsel
Georgia
-$184K
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Investments
26
Two Sigma Investments
New York
$134K -$119K -14,403 -38%
T. Rowe Price Associates
27
T. Rowe Price Associates
Maryland
$120K – – –
Citigroup
28
Citigroup
New York
$109K +$109K +13,218 +232%
Jane Street
29
Jane Street
New York
$105K -$31.7K -3,839 -17%
AI
30
Atom Investors
Texas
$103K +$146K +17,747 New
Group One Trading
31
Group One Trading
Illinois
$97.7K +$11K +1,339 +9%
MIM
32
MetLife Investment Management
New Jersey
$87.7K +$70.5K +8,546 +129%
Deutsche Bank
33
Deutsche Bank
Germany
$83.2K +$119K +14,387 New
Mirae Asset Global ETFs Holdings
34
Mirae Asset Global ETFs Holdings
Hong Kong
$80.6K +$115K +13,950 New
CF
35
Corebridge Financial
Texas
$80.3K +$1.88K +228 +2%
UBS Group
36
UBS Group
Switzerland
$79.3K -$113K -13,676 -50%
Wells Fargo
37
Wells Fargo
California
$77.7K +$2.75K +333 +3%
Wolverine Trading
38
Wolverine Trading
Illinois
$71.3K -$21.8K -2,646 -18%
SG Americas Securities
39
SG Americas Securities
New York
$71K +$101K +12,286 New
JP Morgan Chase
40
JP Morgan Chase
New York
$67.9K +$3.78K +458 +4%
Qube Research & Technologies (QRT)
41
Qube Research & Technologies (QRT)
United Kingdom
$67.6K -$558K -67,590 -85%
Invesco
42
Invesco
Georgia
$63.7K -$3.98K -482 -4%
SEIA
43
Signature Estate & Investment Advisors
California
$62.9K – – –
Pathstone Holdings
44
Pathstone Holdings
New Jersey
$59.3K +$84.7K +10,266 New
KFGK
45
Keystone Financial Group (Kentucky)
Kentucky
$58.2K -$124 -15 -0.1%
New York State Common Retirement Fund
46
New York State Common Retirement Fund
New York
$56.1K -$25.6K -3,100 -24%
Simplex Trading
47
Simplex Trading
Illinois
$55K +$54.6K +6,617 +217%
BNP Paribas Financial Markets
48
BNP Paribas Financial Markets
France
$32.8K +$29.9K +3,630 +177%
Royal Bank of Canada
49
Royal Bank of Canada
Ontario, Canada
$21K +$1.51K +183 +5%
Osaic Holdings
50
Osaic Holdings
Arizona
$16.9K +$1.29K +157 +6%
1
2
3 4 5

INO Hedge Fund Activity: Q3 2024 in Review

98 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q3 2024, worth a combined $49.5M — down 24% from $65.1M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new INO positions and 16 closed out — a net gain of 4 holders — while 27 added to existing stakes and 20 trimmed.

The largest buyer was Vanguard Group, adding an estimated $1.78M. The largest seller was Deep Track Capital, cutting an estimated $2.16M.

  • 98 institutional investors held Inovio Pharmaceuticals (INO) as of Q3 2024, up from 96 in Q2 2024.
  • Funds reported $49.5M of Inovio Pharmaceuticals stock for Q3 2024, down 24% quarter-over-quarter.
  • 20 funds opened new Inovio Pharmaceuticals positions in Q3 2024 and 16 closed out, a net change of +4 holders.
  • The largest Inovio Pharmaceuticals buyer in Q3 2024 was Vanguard Group, an estimated $1.78M added.
  • The largest Inovio Pharmaceuticals seller in Q3 2024 was Deep Track Capital, an estimated $2.16M sold.

Based on aggregated 13F filings for Q3 2024.